Lung Cancer Medicare Access to Precise Testing Act
About This Bill
Committee
Latest Action · November 28, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
H.R. 6321 requires Medicare to cover lung cancer biomarker testing, which identifies specific genetic markers, proteins, or other molecules in a patient's tissue or blood to help determine the best treatment approach. The bill affects Medicare beneficiaries diagnosed with lung cancer who need these precision tests to guide their care decisions. Medicare would cover 100 percent of the reasonable charges for this testing, with coverage beginning January 1, 2027. The bill was introduced in November 2025 and referred to the House Committees on Energy and Commerce and Ways and Means for consideration. This legislation aims to expand access to advanced diagnostic testing that helps doctors provide more personalized and effective lung cancer treatment options.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.